Hostname: page-component-8448b6f56d-tj2md Total loading time: 0 Render date: 2024-04-19T09:51:12.454Z Has data issue: false hasContentIssue false
  • English
  • Français

Retinal microvascular plasticity in a premature neonate

Published online by Cambridge University Press:  31 January 2017

Y. Kandasamy ,
L. Hartley  and
R. Smith
Y. Kandasamy*
Affiliation:
Department of Neonatology, The Townsville Hospital, Townsville, QLD, Australia Mothers and Babies Research Centre, Hunter Medical Research Institute, John Hunter Hospital, The University of Newcastle, Callaghan, NSW, Australia College of Medicine and Dentistry, The James Cook University, Townsville, QLD, Australia
L. Hartley
Affiliation:
Department of Optometry and Vision Science, The University of Melbourne, Melbourne, VIC, Australia
R. Smith
Affiliation:
Mothers and Babies Research Centre, Hunter Medical Research Institute, John Hunter Hospital, The University of Newcastle, Callaghan, NSW, Australia
*
*Address for correspondence: Y. Kandasamy, Department of Neonatology, The Townsville Hospital, 100 Angus Smith Drive, Douglas, QLD 4814, Australia. (Email Yoga.Kandasamy@health.qld.gov.au)
Get access Rights & Permissions [Opens in a new window]

Abstract

Dilation and abnormal tortuosity of retinal vessels are the hallmarks of severe retinopathy of prematurity (ROP) in premature infants. The stages of ROP are defined by vessel appearance at the interface between the vascular and avascular retinal areas. Deregulated signaling pathways involving hypoxia-inducible factors such as vascular endothelial growth factor (VEGF) are involved in the pathogenesis of ROP. VEGF-antagonists are increasingly being used as ‘off-label medication’ to treat this condition, with some success. We present Baby SM (female), who was born prematurely at 24 weeks gestation in a tertiary neonatal intensive care unit, and with a birth weight of 640 g. On screening at 35 weeks postmenstrual age (PMA), she was noted to have ROP, which became severe by 37 weeks PMA. She received one dose of intravitreal VEGF antagonist (Bevacizumab), resulting in a decrease in vessel tortuosity and dilation. However, repeat imaging at 4 weeks showed a re-emergence of vessel tortuosity. We believe the observed changes demonstrate an inherent retinal microvascular plasticity in premature neonates. With improved survival of extremely premature neonates and the availability of retinal imaging technology, we are now able to observe this plasticity.

Keywords

neonateplasticityprematurepretermretinal microvascular
Type
Brief Report
Information
Journal of Developmental Origins of Health and Disease , Volume 8 , Issue 3 , June 2017 , pp. 284 - 286
Check for updates
Copyright
© Cambridge University Press and the International Society for Developmental Origins of Health and Disease 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Han, H-C. Twisted blood vessels: symptoms, etiology and biomechanical mechanisms. J Vasc Res. 2012; 49, 185–197.Google Scholar
2. Turior, R, Onkaew, D, Uyyanonvara, B, Chutinantvarodom, P. Quantification and classification of retinal vessel tortuosity. Science Asia. 2013; 39, 265–277.Google Scholar
3. Hartnett, ME, Martiniuk, D, Byfield, G, et al. Neutralizing VEGF decreases tortuosity and alters endothelial cell division orientation in arterioles and veins in a rat model of ROP: relevance to plus disease. Invest Ophthalmol Vis Sci. 2008; 49, 3107–3114.CrossRefGoogle Scholar
4. Good, WV. Early Treatment for Retinopathy of Prematurity Cooperative Group. The early treatment for retinopathy of prematurity study: structural findings at age 2 years. Br J Ophthalmol. 2006; 90, 1378–1382.Google ScholarPubMed
5. Mintz-Hittner, HA, Kennedy, KA, Chuang, AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011; 364, 603–615.Google Scholar
6. Sankar, MJ, Sankar, J, Mehta, M, Bhat, V, Srinivasan, R. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst Rev. 2016; (2), article no. CD009734.Google Scholar
7. Morin, J, Luu, TM, Superstein, R, et al. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics. 2016; 137, e20153218.Google Scholar
8. Pertl, L, Steinwender, G, Mayer, C, et al. A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity. PLoS One. 2015; 10, e0129383.Google Scholar
9. Kandasamy, Y, Hartley, L, Rudd, D, Smith, R. The association between systemic vascular endothelial growth factor and retinopathy of prematurity in premature infants: a systematic review. Br J Ophthalmol. 2017; 101, 21–24.Google Scholar
10. Jacobsen, JCB, Hornbech, MS, Holstein-Rathlou, N-H. A tissue in the tissue: models of microvascular plasticity. Eur J Pharm Sci. 2009; 36, 51–61.CrossRefGoogle ScholarPubMed